RBRamesh Balusu

Ramesh Balusu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ramesh Balusu has a total of 126 co-authors. Here are the top co-authors by number of shared publications:

  • Kapil N. Bhalla

    Univ. of Kansas Cancer Ctr., Kansas City, KS

    5 shared publications
  • Roy A. Jensen

    University of Kansas Medical Center, Kansas City, KS

    5 shared publications
  • Siddhartha Ganguly

    Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, USA

    5 shared publications
  • Sudhakiranmayi Kuravi

    Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, USA

    5 shared publications
  • Joseph McGuirk

    Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA; The University of Kansas Cancer Center, Kansas City, KS, USA

    4 shared publications
  • Joseph P. McGuirk

    Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA; The University of Kansas Cancer Center, Kansas City, KS, USA

    4 shared publications

Latest Publications

  • Open Access

    Advances in stem cell and cellular therapeutics from the 9th Midwest Conference on Cell Therapy and Regenerative Medicine

    by Ramesh Balusu, Rupal Soder, Nathaniel Dudley, Joseph P. McGuirk, Sunil Abhyankar

  • Open Access

    Splice-modulating strategies targeting the insulin receptor: A novel therapeutic pathway in osteosarcoma

    by Divya R. Singh, Rajvir Singh, Ramesh Balusu, Kishore B. Challagundla

  • Open Access

    Outcomes with HLA-Matched Unrelated Donor Versus Haploidentical Hematopoietic Cell Transplantation: A Single-Center Experience

    by Muhammad Umair Mushtaq, Moazzam Shahzad, Shaun DeJarnette, Joe S Al-Ramahi, Forat Lutfi, Kevin Li, Ramesh Balusu, Nausheen Ahmed, Rajat Bansal, Haitham Abdelhakim, et al.

  • Open Access

    Functional characterization of NPM1–TYK2 fusion oncogene

    by Sudhakiranmayi Kuravi, Riley W. Baker, Muhammad Umair Mushtaq, Irfan Saadi, Tara L. Lin, Carolyn J. Vivian, Anusha Valluripalli, Sunil Abhyankar, Siddhartha Ganguly, Wei Cui, et al.

    Gene fusions are known to drive many human cancers. Therefore, the functional characterization of newly discovered fusions is critical to understanding the oncobiology of these tumors and to enable therapeutic development. NPM1–TYK2 is a novel fusion identified in CD30 + lymphoproliferative disorders, and here we present the functional evaluation of this fusion gene as an oncogene. The chimeric protein consists of the amino-terminus of nucleophosmin 1 (NPM1) and the carboxyl-terminus of tyrosine kinase 2 (TYK2), including the kinase domain. Using in vitro lymphoid cell transformation assays and in vivo tumorigenic xenograft models we present direct evidence that the fusion gene is an oncogene. NPM1 fusion partner provides the critical homodimerization needed for the fusion kinase constitutive activation and downstream signaling that are responsible for cell transformation. As a result, our studies identify NPM1–TYK2 as a novel fusion oncogene and suggest that inhibition of fusion homodimerization could be a precision therapeutic approach in cutaneous T-cell lymphoma patients expressing this chimera.


  • Open Access

    Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma

    by V. Subbiah, S. Kuravi, S. Ganguly, D.R. Welch, C.J. Vivian, M.U. Mushtaq, A. Hegde, S. Iyer, A. Behrang, S.M. Ali, et al.


  • Open Access

    Preclinical Evaluation of Gilteritinib on NPM1-ALK–Driven Anaplastic Large Cell Lymphoma Cells

    by Sudhakiranmayi Kuravi, Janice Cheng, Gabrielle Fangman, Kishore Polireddy, Sophia McCormick, Tara L. Lin, Anurag K. Singh, Sunil Abhyankar, Siddhartha Ganguly, Danny R. Welch, et al.

    Anaplastic large cell lymphoma (ALCL) is an aggressive type of non-Hodgkin lymphoma. More than three-fourths of anaplastic lymphoma kinase (ALK)-positive ALCL cases express the nucleophosmin 1 (NPM1)-ALK fusion gene as a result of t(2;5) chromosomal translocation. The homodimerization of NPM1-ALK fusion protein mediates constitutive activation of the chimeric tyrosine kinase activity and downstream signaling pathways responsible for lymphoma cell proliferation and survival. Gilteritinib is a tyrosine kinase inhibitor recently approved by the FDA for the treatment of FMS-like tyrosine kinase mutation–positive acute myeloid leukemia. In this study, we demonstrate for the first time gilteritinib-mediated growth inhibitory effects on NPM1-ALK–driven ALCL cells. We utilized a total of five ALCL model cell lines, including both human and murine. Gilteritinib treatment inhibits NPM1-ALK fusion kinase phosphorylation and downstream signaling, resulting in induced apoptosis. Gilteritinib-mediated apoptosis was associated with caspase 3/9, PARP cleavage, the increased expression of proapoptotic protein BAD, and decreased expression of antiapoptotic proteins, survivin and MCL-1. We also found downregulation of fusion kinase activity resulted in decreased c-Myc protein levels. Furthermore, cell-cycle analysis indicated gilteritinib induced G0–G1-phase cell-cycle arrest and reduced CD30 expression. In summary, our preclinical studies explored the novel therapeutic potential of gilteritinib in the treatment of ALCL cells expressing NPM1-ALK and potentially in other ALK or ALK fusion–driven hematologic or solid malignancies. Implications: Our preclinical results explore the use of gilteritinib for the treatment of NPM1-ALK–driven ALCL cells and pave a path for developing future clinical trials.


  • Open Access

    Targeted Therapy for EBV-Associated B-cell Neoplasms

    by Siddhartha Ganguly, Sudhakiranmayi Kuravi, Satyanarayana Alleboina, Giridhar Mudduluru, Roy A. Jensen, Joseph P. McGuirk, Ramesh Balusu

    Epstein–Barr virus (EBV) is directly implicated in several B-cell lymphoid malignancies. EBV-associated lymphomas are characterized by prominent activation of the NF-κB pathway and targeting this pathway establishes a rationale for a therapeutic approach. The ubiquitin/proteasome signaling plays an essential role in the regulation of the NF-κB pathway. Ixazomib is an FDA-approved, orally bioavailable proteasome inhibitor. Here we report the first preclinical evaluation of ixazomib-mediated growth-inhibitory effects on EBV-infected B-lymphoblastoid cell lines Raji and Daudi. Ixazomib induced apoptosis in these cell lines in a dose-dependent manner. Cell-cycle analysis demonstrated ixazomib treatment induced cell-cycle arrest at the G2–M phase with a concomitant decrease in G0–G1 and S phases. The results further revealed an increase in p53, p21, and p27 levels and a decrease in survivin and c-Myc protein levels. Mechanistically, ixazomib treatment resulted in the accumulation of polyubiquitinated proteins, including phosphorylated IκBα with a significant reduction of p65 subunit nuclear translocation. Altogether, our preclinical data support the rationale for in vivo testing of ixazomib in EBV-associated B-cell neoplasms. Implications: This preclinical study supports the use of oral proteasome inhibitor ixazomib for targeting NF-κB signaling in the treatment of EBV-associated B-cell neoplasms. Visual Overview: http://mcr.aacrjournals.org/content/molcanres/17/4/839/F1.large.jpg.


  • Open Access

    CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas

    by Sudhakiranmayi Kuravi, Elizabeth Parrott, Giridhar Mudduluru, Janice Cheng, Siddhartha Ganguly, Yogen Saunthararajah, Roy A. Jensen, Brian S. Blagg, Joseph P. McGuirk, Ramesh Balusu


  • Silver carbene complexes: An emerging class of anticancer agents

    by Shravankumar Kankala, Niranjan Thota, Fredrik Björkling, Myles K. Taylor, Ravinder Vadde, Ramesh Balusu

    Cancer is a major global health problem with large therapeutic challenges. Although substantial progress has been made in cancer therapy, there still remains a need to develop novel and effective treatment strategies to treat several relapsed and refractory cancers. Recently, there has been growing demand for considering organometallics as antineoplastic agents. This review is focused on a group of organometallics, silver N‐heterocyclic carbene complexes (SCCs) and their anticancer efficacy in targeting multiple pathways in various in vitro cancer model systems. However, the precise molecular mechanism of SCCs anticancer properties remains unclear. Here, we discuss the SCCs chemistry, potential molecular targets, possible molecular mechanism of action, and their application in cancer therapies.


  • Open Access

    Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates

    by Xiaorong Gu, Quteba Ebrahem, Reda Z. Mahfouz, Metis Hasipek, Francis Enane, Tomas Radivoyevitch, Nicolas Rapin, Bartlomiej Przychodzen, Zhenbo Hu, Ramesh Balusu, et al.

    Nucleophosmin (NPM1) is among the most frequently mutated genes in acute myeloid leukemia (AML). It is not known, however, how the resulting oncoprotein mutant NPM1 is leukemogenic. To reveal the cellular machinery in which NPM1 participates in myeloid cells, we analyzed the endogenous NPM1 protein interactome by mass spectrometry and discovered abundant amounts of the master transcription factor driver of monocyte lineage differentiation PU.1 (also known as SPI1). Mutant NPM1, which aberrantly accumulates in cytoplasm, dislocated PU.1 into cytoplasm with it. CEBPA and RUNX1, the master transcription factors that collaborate with PU.1 to activate granulomonocytic lineage fates, remained nuclear; but without PU.1, their coregulator interactions were toggled from coactivators to corepressors, repressing instead of activating more than 500 granulocyte and monocyte terminal differentiation genes. An inhibitor of nuclear export, selinexor, by locking mutant NPM1/PU.1 in the nucleus, activated terminal monocytic fates. Direct depletion of the corepressor DNA methyltransferase 1 (DNMT1) from the CEBPA/RUNX1 protein interactome using the clinical drug decitabine activated terminal granulocytic fates. Together, these noncytotoxic treatments extended survival by more than 160 days versus vehicle in a patient-derived xenotransplant model of NPM1/FLT3-mutated AML. In sum, mutant NPM1 represses monocyte and granulocyte terminal differentiation by disrupting PU.1/CEBPA/RUNX1 collaboration, a transforming action that can be reversed by pharmacodynamically directed dosing of clinical small molecules.